about
Kinase inhibitors from marine spongesFunctional deregulation of KIT: link to mast cell proliferative diseases and other neoplasmsStructure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistanceThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyA novel quantitative kinase assay using bacterial surface display and flow cytometryEmbryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formationPhosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA1, LPA2, and LPA3.Protein tyrosine kinases and protein tyrosine phosphatases are involved in abscisic acid-dependent processes in Arabidopsis seeds and suspension cells.Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screeningSARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism.New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsSystemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor.Chiral kinase inhibitors.Receptor tyrosine kinases and schistosome reproduction: new targets for chemotherapyOncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Agonism and antagonism at the insulin receptor.Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation.Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.A fluorescence-based high throughput assay for the determination of small molecule-human serum albumin protein binding.The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers.Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Signal processing by protein tyrosine phosphorylation in plants.Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system.Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.Inhibition of janus kinase 2 by compound AG490 suppresses the proliferation of MDA-MB-231 cells via up-regulating SARI (suppressor of AP-1, regulated by IFN).Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyreneCellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation.Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Modulation of dorsal root ganglion development by ErbB signaling and the scaffold protein Sorbs3
P2860
Q26864357-12827877-D67A-462E-B2E9-AB9F68BCD05EQ26995624-3804BFDF-718D-4204-BEE8-DF7F8A8A21CEQ27678586-3712D896-5669-4D59-9267-C225395516C4Q28073335-A8680307-D6B9-48D3-8B5F-8DE2894A37A2Q28535179-47CE0771-B855-48B8-AFB4-B65D4615C62DQ28752378-943C49F5-B6B3-4D8D-879F-4F1D34A43F79Q30400167-69AF9809-FB9F-4DBE-9657-C202CECF4AF5Q33366334-C55475C7-F68D-469C-A801-392203CCF187Q33412050-16F38E93-B67F-4EBF-962A-2EEC1B3840EEQ33553351-CAF5E72F-5A55-4A43-BDB9-C1A75D67E4E6Q33622982-F3A1907F-51DE-44B3-B167-F4EEF388D045Q33754081-2D147BD9-22E5-46CA-B7B1-344B5F89A907Q33811207-2EE58F37-ECA2-4625-A1AE-72DF16517500Q33917776-502CD2CA-67DA-4904-B6DA-6BCDB2A047F2Q33943421-57EFB898-1126-4C8F-B187-7CAB62A19D64Q34391968-59E0E52A-3881-494C-9364-AAB8B1E1078CQ34540334-748C6110-89AC-4075-80A6-255911D74D63Q34801318-5A382B15-C5A6-44C3-B4E3-C6EA8519F26BQ34992505-79EAB6CF-2D79-491A-861C-9299FC191593Q35081931-0801C92A-5B06-49E9-8E99-11F8166F8E43Q35111380-F6275CFA-8E42-4659-9998-9399C04CA0D8Q35150412-3D4E6E5E-287A-4730-B563-8B8557DD8466Q35250091-BD607E0D-F73D-46FB-8E10-6DD65C175798Q35311474-13C6E494-B380-4EE2-9B54-5CAF86D99672Q35631635-B553135F-0B58-4B45-93E9-FD4CD96C11A7Q35671262-60D735C6-094C-48B1-9F39-DC6E27FD57D0Q35676118-947C8A0E-9BA0-4C05-A555-E9A1DD67A9E2Q35816817-3582C6F7-1BC7-4BFF-B0DB-66C2AA93152BQ35875900-8D2020E9-D5A9-4C2F-B3DE-14E70276D287Q35906313-76775A63-DA4F-4D9B-B793-A1DB2FCD7B0AQ35942258-DA5D7C8D-D58D-4D43-BBF5-88A931D82D50Q36020691-A510188A-6DCA-4C20-9E71-E0E1D1AB9FCBQ36103111-A29D86A5-B7DE-4E9F-88D8-6F4F71F6F85EQ36159154-DB797865-353F-49A0-AC9A-3FF46C076CEBQ36414193-F1A9C180-4FFE-4ECA-B974-D47435D3885FQ36686034-3C652BA4-63EB-4BC2-82C5-C9DC5626CF81Q36797398-AB16FA2D-A48E-4185-8785-F062043AE999Q36803657-24813C70-EA0C-4F8C-AD27-068C75DB8444Q36842503-1C501092-2D88-4778-A1C6-F6FE7A80A186Q37177986-B2C383FB-4366-4BA9-BD9D-A027589EF4B0
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Tyrphostins and other tyrosine kinase inhibitors.
@ast
Tyrphostins and other tyrosine kinase inhibitors.
@en
Tyrphostins and other tyrosine kinase inhibitors.
@nl
type
label
Tyrphostins and other tyrosine kinase inhibitors.
@ast
Tyrphostins and other tyrosine kinase inhibitors.
@en
Tyrphostins and other tyrosine kinase inhibitors.
@nl
prefLabel
Tyrphostins and other tyrosine kinase inhibitors.
@ast
Tyrphostins and other tyrosine kinase inhibitors.
@en
Tyrphostins and other tyrosine kinase inhibitors.
@nl
P1476
Tyrphostins and other tyrosine kinase inhibitors.
@en
P2093
Alexander Levitzki
Eyal Mishani
P304
P356
10.1146/ANNUREV.BIOCHEM.75.103004.142657
P577
2006-01-01T00:00:00Z